Literature DB >> 16200404

[Inflammatory muscle diseases: dermatomyositis, polymyositis, and inclusion body myositis].

E Genth1.   

Abstract

Dermatomyositis, polymyositis, inclusion body myositis and myositis overlap syndromes are systemic immune disorders of unknown origin with muscle weakness and elevated values of creatinkinase in the serum. Muscle biopsy is pivotal for a proper clinical diagnosis. Extramuscular findings at the skin, the joints or internal organs (lung, heart) are characteristic for the different clinical presentations of dermato- or polymyositis and are usually absent in inclusion body myositis. With the exception of inclusion body myositis myositis-associated autoantibodies are frequently present and associated with distinct clinical manifestations (e. g. antisynthetase syndrome). The rate of malignancy is elevated for several years after onset of myositis. Especially in polymyositis an appropriate differential diagnosis of infectious, endocrine, metabolic or neuromuscular causes of muscle disease is necessary. Glucocorticosteroids are the first choice of treatment in dermato- or polymyositis. Methotraxate, azathioprine, cyclophosphamamide, i.v. immunoglobulins and other drugs are used in diseases courses with continuous high dose requirement of corticosteroids.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16200404     DOI: 10.1007/s00108-005-1496-4

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  27 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

Review 2.  Inflammatory myopathies: how to treat the difficult cases.

Authors:  F L Mastaglia; P J Zilko
Journal:  J Clin Neurosci       Date:  2003-01       Impact factor: 1.961

Review 3.  Autoantibodies in polymyositis.

Authors:  I N Targoff
Journal:  Rheum Dis Clin North Am       Date:  1992-05       Impact factor: 2.670

4.  Antibody to signal recognition particle in polymyositis.

Authors:  I N Targoff; A E Johnson; F W Miller
Journal:  Arthritis Rheum       Date:  1990-09

5.  Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study.

Authors:  B Sigurgeirsson; B Lindelöf; O Edhag; E Allander
Journal:  N Engl J Med       Date:  1992-02-06       Impact factor: 91.245

Review 6.  Myositis: an update on pathogenesis.

Authors:  Lisa Christopher-Stine; Paul H Plotz
Journal:  Curr Opin Rheumatol       Date:  2004-11       Impact factor: 5.006

Review 7.  Polymyositis and dermatomyositis.

Authors:  Marinos C Dalakas; Reinhard Hohlfeld
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

Review 8.  NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy.

Authors:  P H Plotz; L G Rider; I N Targoff; N Raben; T P O'Hanlon; F W Miller
Journal:  Ann Intern Med       Date:  1995-05-01       Impact factor: 25.391

9.  Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy.

Authors:  M M Joffe; L A Love; R L Leff; D D Fraser; I N Targoff; J E Hicks; P H Plotz; F W Miller
Journal:  Am J Med       Date:  1993-04       Impact factor: 4.965

Review 10.  Treatment of idiopathic inflammatory myopathies with cyclophosphamide pulses: clinical experience and a review of the literature.

Authors:  S De Vita; V Fossaluzza
Journal:  Acta Neurol Belg       Date:  1992       Impact factor: 2.396

View more
  4 in total

Review 1.  [Current treatments of dermatomyositis and polymyositis].

Authors:  J Richter; C Iking-Konert
Journal:  Z Rheumatol       Date:  2007-12       Impact factor: 1.372

Review 2.  Pathogenesis, classification and treatment of inflammatory myopathies.

Authors:  Mei Zong; Ingrid E Lundberg
Journal:  Nat Rev Rheumatol       Date:  2011-04-05       Impact factor: 20.543

3.  [Severe dysphagia and erythrodermia in a 59-year-old man].

Authors:  M A Zuber; M Kouba; S E Rudolph; M Weller; P Hrdlicka
Journal:  Internist (Berl)       Date:  2013-03       Impact factor: 0.743

4.  Paraneoplastic dermatomyositis with carcinoma cervix: a rare clinical association.

Authors:  Sumir Kumar; B B Mahajan; Sandeep Kaur; Amarbir Singh
Journal:  Case Rep Dermatol Med       Date:  2014-12-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.